Teva Offers Antitrust Concessions For $40.5B Generics Deal
Teva Pharmaceutical Industries Ltd. has made commitments to the European Commission in an effort to win antitrust approval for the drugmaker's proposed, $40.5 billion acquisition of Allergan PLC's generics business, the...To view the full article, register now.
Already a subscriber? Click here to view full article